TransMedics Group (TMDX) Stock Forecast, Price Target & Predictions
TMDX Stock Forecast
TransMedics Group stock forecast is as follows: an average price target of $126.75 (represents a 49.17% upside from TMDX’s last price of $84.97) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
TMDX Price Target
The average price target for TransMedics Group (TMDX) is $126.75 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $45.00. This represents a potential 49.17% upside from TMDX's last price of $84.97.
TMDX Analyst Ratings
According to 9 Wall Street analysts, TransMedics Group's rating consensus is 'Buy'. The analyst rating breakdown for TMDX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TransMedics Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 29, 2024 | Joe Vruwink | Robert W. Baird | $150.00 | $88.70 | 69.11% | 76.53% |
| Oct 29, 2024 | Jason Mills | Canaccord Genuity | $109.00 | $126.24 | -13.66% | 28.28% |
| Oct 29, 2024 | Mike Matson | Needham | $109.00 | $126.24 | -13.66% | 28.28% |
| Oct 29, 2024 | Suraj Kalia | Oppenheimer | $125.00 | $126.24 | -0.98% | 47.11% |
| Sep 23, 2024 | David Rescott | Robert W. Baird | $200.00 | $159.50 | 25.39% | 135.38% |
| Sep 04, 2024 | Matt O'Brien | Piper Sandler | $180.00 | $158.42 | 13.62% | 111.84% |
| Aug 21, 2024 | Mike Matson | Needham | $208.00 | $166.18 | 25.17% | 144.79% |
| Aug 01, 2024 | William Plovanic | Canaccord Genuity | $169.00 | $164.02 | 3.04% | 98.89% |
| Aug 01, 2024 | Suraj Kalia | Oppenheimer | $200.00 | $142.26 | 40.59% | 135.38% |
| Jul 15, 2024 | Patrick Wood | Morgan Stanley | $145.00 | $142.19 | 1.98% | 70.65% |
The latest TransMedics Group stock forecast, released on Oct 29, 2024 by Joe Vruwink from Robert W. Baird, set a price target of $150.00, which represents a 69.11% increase from the stock price at the time of the forecast ($88.70), and a 76.53% increase from TMDX last price ($84.97).
TransMedics Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 7 | 12 |
| Avg Price Target | $123.25 | $154.43 | $159.67 |
| Last Closing Price | $84.97 | $84.97 | $84.97 |
| Upside/Downside | 45.05% | 81.75% | 87.91% |
In the current month, the average price target of TransMedics Group stock is $123.25, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 45.05% increase as opposed to TransMedics Group's last price of $84.97. This month's average price target is down -20.19% compared to last quarter, and down -22.81% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | William Blair | Outperform | Outperform | Hold |
| Oct 29, 2024 | Stephens | Buy | Buy | Hold |
| Oct 29, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Oct 29, 2024 | Needham | Buy | Buy | Hold |
| Oct 29, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 24, 2024 | Stephens | Buy | Buy | Hold |
| Sep 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 04, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 26, 2024 | Canaccord Genuity | Buy | Buy | Hold |
TransMedics Group's last stock rating was published by William Blair on Oct 29, 2024. The company gave TMDX a "Outperform" rating, the same as its previous rate.
TransMedics Group Financial Forecast
TransMedics Group Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $66.43M | $52.47M | $41.55M | $31.38M | $25.68M | $20.52M | $15.88M | $9.67M | $5.37M | $8.17M | $7.05M | $7.63M | $7.09M | $3.39M | $7.53M | $6.06M | $7.21M |
| Avg Forecast | $164.16M | $155.41M | $154.02M | $133.27M | $147.15M | $140.33M | $140.31M | $123.85M | $113.48M | $115.00M | $98.84M | $83.78M | $68.49M | $49.19M | $42.42M | $37.93M | $24.45M | $18.88M | $16.27M | $9.66M | $7.51M | $6.34M | $7.42M | $7.10M | $6.06M | $5.55M | $2.75M | $7.14M | $6.97M | $6.67M |
| High Forecast | $170.35M | $161.27M | $159.82M | $138.30M | $152.70M | $145.62M | $145.60M | $128.42M | $116.32M | $115.43M | $98.84M | $86.94M | $69.81M | $49.19M | $44.02M | $39.36M | $25.37M | $18.88M | $16.27M | $9.66M | $7.51M | $6.34M | $7.42M | $7.10M | $6.06M | $5.55M | $2.75M | $7.14M | $6.97M | $6.67M |
| Low Forecast | $156.87M | $148.51M | $147.18M | $127.35M | $140.62M | $134.10M | $134.08M | $119.31M | $110.77M | $114.57M | $98.84M | $80.06M | $67.75M | $49.19M | $40.54M | $36.25M | $23.36M | $18.88M | $16.27M | $9.66M | $7.51M | $6.34M | $7.42M | $7.10M | $6.06M | $5.55M | $2.75M | $7.14M | $6.97M | $6.67M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.35% | 1.24% | 1.10% | 1.28% | 1.36% | 1.26% | 1.64% | 1.29% | 0.85% | 1.10% | 0.99% | 1.26% | 1.28% | 1.23% | 1.05% | 0.87% | 1.08% |
TransMedics Group's average Quarter revenue forecast for Dec 23 based on 4 analysts is $68.49M, with a low forecast of $67.75M, and a high forecast of $69.81M. TMDX's average Quarter revenue forecast represents a 3.11% increase compared to the company's last Quarter revenue of $66.43M (Sep 23).
TransMedics Group EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-28.34M | $1.52M | $-1.53M | $-5.69M | $-5.73M | $-10.53M | $-9.09M | $-11.21M | $-11.52M | $-9.25M | $-6.52M | $-4.90M | $-3.71M | $-7.12M | $-7.43M | $-7.75M | $-6.85M |
| Avg Forecast | $-107.54M | $-101.81M | $-100.89M | $-87.30M | $-96.40M | $-91.93M | $-91.92M | $-81.13M | $-74.34M | $-75.33M | $-64.75M | $-8.67M | $-44.87M | $-32.22M | $-27.79M | $-7.88M | $-11.15M | $-12.36M | $-10.66M | $-7.17M | $-4.92M | $-4.16M | $-4.86M | $-6.52M | $-3.97M | $-3.64M | $-1.80M | $-7.06M | $-4.56M | $-4.37M |
| High Forecast | $-102.76M | $-97.29M | $-96.41M | $-83.43M | $-92.12M | $-87.85M | $-87.83M | $-78.16M | $-72.56M | $-75.05M | $-64.75M | $-6.94M | $-44.38M | $-32.22M | $-26.56M | $-6.31M | $-8.92M | $-12.36M | $-10.66M | $-5.73M | $-4.92M | $-4.16M | $-4.86M | $-5.21M | $-3.97M | $-3.64M | $-1.80M | $-5.65M | $-4.56M | $-4.37M |
| Low Forecast | $-111.59M | $-105.65M | $-104.70M | $-90.60M | $-100.03M | $-95.39M | $-95.38M | $-84.13M | $-76.20M | $-75.61M | $-64.75M | $-10.41M | $-45.73M | $-32.22M | $-28.84M | $-9.46M | $-13.38M | $-12.36M | $-10.66M | $-8.60M | $-4.92M | $-4.16M | $-4.86M | $-7.82M | $-3.97M | $-3.64M | $-1.80M | $-8.47M | $-4.56M | $-4.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | -0.05% | 0.19% | 0.51% | 0.46% | 0.99% | 1.27% | 2.28% | 2.77% | 1.90% | 1.00% | 1.23% | 1.02% | 3.95% | 1.05% | 1.70% | 1.57% |
2 analysts predict TMDX's average Quarter EBITDA for Sep 23 to be $-32.22M, with a high of $-32.22M and a low of $-32.22M. This is -2212.95% lower than TransMedics Group's previous annual EBITDA (Jun 23) of $1.52M.
TransMedics Group Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.42M | $-1.00M | $-2.64M | $-6.72M | $-7.43M | $-11.52M | $-10.56M | $-12.67M | $-12.96M | $-10.67M | $-7.92M | $-6.31M | $-5.09M | $-8.50M | $-8.85M | $-9.18M | $-8.28M |
| Avg Forecast | $20.63M | $19.40M | $19.34M | $16.56M | $15.93M | $15.03M | $16.07M | $11.22M | $7.30M | $10.47M | $7.52M | $-10.54M | $-2.47M | $-5.79M | $-4.67M | $-9.58M | $-12.61M | $-14.54M | $-12.28M | $-8.71M | $-15.19M | $-12.54M | $-9.96M | $-7.92M | $-8.78M | $-11.30M | $-14.88M | $-8.41M | $-13.76M | $-15.79M |
| High Forecast | $21.64M | $20.35M | $20.29M | $17.37M | $16.71M | $15.77M | $16.86M | $12.66M | $9.73M | $10.48M | $7.53M | $-8.43M | $-1.48M | $-5.45M | $-4.40M | $-7.66M | $-10.09M | $-14.54M | $-12.28M | $-6.97M | $-15.19M | $-12.54M | $-9.96M | $-6.33M | $-8.78M | $-11.30M | $-14.88M | $-6.73M | $-13.76M | $-15.79M |
| Low Forecast | $19.44M | $18.28M | $18.22M | $15.60M | $15.01M | $14.17M | $15.14M | $9.04M | $4.87M | $10.46M | $7.52M | $-12.65M | $-4.69M | $-6.07M | $-4.90M | $-11.50M | $-15.13M | $-14.54M | $-12.28M | $-10.45M | $-15.19M | $-12.54M | $-9.96M | $-9.50M | $-8.78M | $-11.30M | $-14.88M | $-10.09M | $-13.76M | $-15.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.39% | 0.21% | 0.28% | 0.53% | 0.51% | 0.94% | 1.21% | 0.83% | 1.03% | 1.07% | 1.00% | 0.72% | 0.45% | 0.57% | 1.05% | 0.67% | 0.52% |
TransMedics Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TMDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TransMedics Group SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $30.65M | $29.36M | $24.98M | $21.73M | $16.85M | $17.38M | $13.94M | $12.00M | $10.34M | $9.16M | $6.97M | $6.18M | $5.49M | $5.87M | $6.65M | $6.17M | $6.52M |
| Avg Forecast | $145.84M | $138.07M | $136.83M | $118.40M | $130.73M | $124.67M | $124.66M | $110.03M | $100.82M | $102.17M | $87.81M | $9.28M | $60.85M | $43.70M | $37.69M | $8.44M | $11.94M | $16.77M | $14.46M | $7.67M | $6.67M | $5.64M | $6.59M | $6.97M | $5.39M | $4.93M | $2.44M | $6.32M | $6.19M | $5.93M |
| High Forecast | $151.34M | $143.28M | $141.99M | $122.87M | $135.66M | $129.37M | $129.36M | $114.09M | $103.34M | $102.55M | $87.82M | $11.14M | $62.02M | $43.70M | $39.11M | $10.13M | $14.33M | $16.77M | $14.46M | $9.21M | $6.67M | $5.64M | $6.59M | $8.37M | $5.39M | $4.93M | $2.44M | $7.58M | $6.19M | $5.93M |
| Low Forecast | $139.37M | $131.94M | $130.75M | $113.14M | $124.93M | $119.14M | $119.12M | $106.00M | $98.41M | $101.78M | $87.81M | $7.43M | $60.19M | $43.70M | $36.02M | $6.75M | $9.55M | $16.77M | $14.46M | $6.14M | $6.67M | $5.64M | $6.59M | $5.58M | $5.39M | $4.93M | $2.44M | $5.06M | $6.19M | $5.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.70% | 0.78% | 2.96% | 1.82% | 1.00% | 1.20% | 1.82% | 1.80% | 1.83% | 1.39% | 1.00% | 1.15% | 1.11% | 2.40% | 1.05% | 1.00% | 1.10% |
TransMedics Group's average Quarter SG&A projection for Dec 23 is $60.85M, based on 4 Wall Street analysts, with a range of $60.19M to $62.02M. The forecast indicates a 98.51% rise compared to TMDX last annual SG&A of $30.65M (Sep 23).
TransMedics Group EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.78 | $-0.03 | $-0.08 | $-0.21 | $-0.25 | $-0.41 | $-0.38 | $-0.46 | $-0.47 | $-0.39 | $-0.29 | $-0.23 | $-0.19 | $-0.36 | $-0.42 | $-0.43 | $-0.39 |
| Avg Forecast | $0.58 | $0.54 | $0.54 | $0.46 | $0.45 | $0.42 | $0.45 | $0.31 | $0.20 | $0.29 | $0.21 | $-0.02 | $-0.07 | $-0.16 | $-0.13 | $-0.25 | $-0.30 | $-0.41 | $-0.35 | $-0.38 | $-0.43 | $-0.36 | $-0.28 | $-0.29 | $-0.25 | $-0.32 | $-0.42 | $-0.40 | $-0.39 | $-0.45 |
| High Forecast | $0.61 | $0.57 | $0.57 | $0.49 | $0.47 | $0.44 | $0.47 | $0.35 | $0.27 | $0.29 | $0.21 | $-0.02 | $-0.04 | $-0.15 | $-0.12 | $-0.23 | $-0.28 | $-0.41 | $-0.35 | $-0.38 | $-0.43 | $-0.36 | $-0.28 | $-0.29 | $-0.25 | $-0.32 | $-0.42 | $-0.40 | $-0.39 | $-0.45 |
| Low Forecast | $0.54 | $0.51 | $0.51 | $0.44 | $0.42 | $0.40 | $0.42 | $0.25 | $0.14 | $0.29 | $0.21 | $-0.02 | $-0.13 | $-0.17 | $-0.14 | $-0.26 | $-0.31 | $-0.41 | $-0.35 | $-0.38 | $-0.43 | $-0.36 | $-0.28 | $-0.29 | $-0.25 | $-0.32 | $-0.42 | $-0.40 | $-0.39 | $-0.45 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.81% | 0.24% | 0.33% | 0.70% | 0.61% | 1.18% | 1.00% | 1.07% | 1.32% | 1.38% | 1.00% | 0.92% | 0.59% | 0.85% | 1.06% | 1.10% | 0.87% |
According to undefined Wall Street analysts, TransMedics Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TMDX previous annual EPS of $NaN (undefined).
TransMedics Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TELA | TELA Bio | $2.85 | $12.50 | 338.60% | Buy |
| DCTH | Delcath Systems | $10.77 | $22.00 | 104.27% | Buy |
| NPCE | NeuroPace | $6.37 | $12.88 | 102.20% | Buy |
| OFIX | Orthofix Medical | $17.33 | $31.00 | 78.88% | - |
| LUNG | Pulmonx | $7.12 | $11.93 | 67.56% | Buy |
| INMD | InMode | $17.38 | $27.50 | 58.23% | Hold |
| TMDX | TransMedics Group | $84.97 | $126.75 | 49.17% | Buy |
| NARI | Inari Medical | $48.93 | $66.11 | 35.11% | Buy |
| INSP | Inspire Medical Systems | $192.71 | $238.00 | 23.50% | Buy |
| PODD | Insulet | $237.44 | $270.93 | 14.10% | Buy |
| SILK | Silk Road Medical | $27.49 | $30.58 | 11.24% | Buy |
| MASI | Masimo | $147.39 | $160.20 | 8.69% | Buy |
| CVRX | CVRx | $15.05 | $16.33 | 8.50% | Buy |
| PEN | Penumbra | $229.51 | $224.85 | -2.03% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
TMDX Forecast FAQ
Is TransMedics Group a good buy?
Yes, according to 9 Wall Street analysts, TransMedics Group (TMDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 77.78% of TMDX's total ratings.
What is TMDX's price target?
TransMedics Group (TMDX) average price target is $126.75 with a range of $45 to $180, implying a 49.17% from its last price of $84.97. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will TransMedics Group stock go up soon?
According to Wall Street analysts' prediction for TMDX stock, the company can go up by 49.17% (from the last price of $84.97 to the average price target of $126.75), up by 111.84% based on the highest stock price target, and down by -47.04% based on the lowest stock price target.
Can TransMedics Group stock reach $130?
TMDX's highest twelve months analyst stock price target of $180 supports the claim that TransMedics Group can reach $130 in the near future.
What is TransMedics Group's current price target trend?
4 Wall Street analysts forecast a $123.25 price target for TransMedics Group (TMDX) this month, up 45.05% from its last price of $84.97. Compared to the last 3 and 12 months, the average price target increased by 81.75% and increased by 87.91%, respectively.
What are TransMedics Group's analysts' financial forecasts?
TransMedics Group's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $551.65M (high $572.35M, low $528.11M), average EBITDA is $-361M (high $-346M, low $-375M), average net income is $58.25M (high $62M, low $53.36M), average SG&A $490.1M (high $508.48M, low $469.19M), and average EPS is $1.63 (high $1.74, low $1.5). TMDX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $606.86M (high $629.74M, low $579.91M), average EBITDA is $-398M (high $-380M, low $-413M), average net income is $75.93M (high $79.65M, low $71.55M), average SG&A $539.15M (high $559.48M, low $515.21M), and average EPS is $2.13 (high $2.23, low $2.01).
Did the TMDX's actual financial results beat the analysts' financial forecasts?
Based on TransMedics Group's last annual report (Dec 2023), the company's revenue was $241.62M, beating the average analysts forecast of $198.04M by 22.01%. Apple's EBITDA was $-28.727M, missing the average prediction of $-113M by -74.53%. The company's net income was $-25.028M, beating the average estimation of $-22.504M by 11.21%. Apple's SG&A was $119.55M, missing the average forecast of $150.68M by -20.66%. Lastly, the company's EPS was $-0.0008, missing the average prediction of $-0.608 by -99.87%. In terms of the last quarterly report (Sep 2023), TransMedics Group's revenue was $66.43M, beating the average analysts' forecast of $49.19M by 35.05%. The company's EBITDA was $-28.335M, missing the average prediction of $-32.222M by -12.06%. TransMedics Group's net income was $-25.422M, beating the average estimation of $-5.787M by 339.31%. The company's SG&A was $30.65M, missing the average forecast of $43.7M by -29.86%. Lastly, the company's EPS was $-0.78, beating the average prediction of $-0.162 by 380.98%